Epidermal growth factor receptor-directed therapy in esophageal cancer

A. U. Pande, R. V. Iyer, A. Rani, S. Maddipatla, G. Y. Yang, C. E. Nwogu, J. D. Black, C. M. Levea, M. M. Javle

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Esophageal adenocarcinoma (EAC) is one of the fastest growing malignancies in the US. The long-term survival of patients with this cancer remains poor; only 25% of patients undergoing surgical excision are alive after 5 years. Multimodal programs that incorporate radiotherapy, chemotherapy and surgery for localized tumors may result in a modest survival advantage. However, significant strides in this disease can result from the inclusion of targeted therapies. The epidermal growth factor receptor (EGFR) family represents one such target and is receiving increasing attention due to the advent of specific inhibitors. Studies conducted by us and others have shown that the overexpression of EGFR family signaling intermediates is common in Barrett's esophagus and EAC. In the latter case, EGFR expression may have prognostic significance. EGFR inhibitors, including oral tyrosine kinase inhibitors and monoclonal antibodies, result in a synergistic antitumor effect with chemotherapeutic agents or with radiotherapy. Therefore, several ongoing studies include EGFR-directed therapy either alone or in combination with chemoradiotherapy for this disease. Our study of gefitinib, oxaliplatin and radiotherapy suggested that gefitinib can be safely incorporated into an oxaliplatin-based chemoradiation program for esophageal cancer, although the clinical activity of this combination is modest. Herein, we review the current literature on this subject.

Original languageEnglish (US)
Pages (from-to)281-289
Number of pages9
JournalONCOLOGY
Volume73
Issue number5-6
DOIs
StatePublished - Jun 1 2008

Fingerprint

Esophageal Neoplasms
Epidermal Growth Factor Receptor
oxaliplatin
Radiotherapy
Adenocarcinoma
Therapeutics
Neoplasms
Barrett Esophagus
Survival
Chemoradiotherapy
Protein-Tyrosine Kinases
Monoclonal Antibodies
Drug Therapy
gefitinib

Keywords

  • Barrett's esophagus
  • Epidermal growth factor receptor
  • Esophageal neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pande, A. U., Iyer, R. V., Rani, A., Maddipatla, S., Yang, G. Y., Nwogu, C. E., ... Javle, M. M. (2008). Epidermal growth factor receptor-directed therapy in esophageal cancer. ONCOLOGY, 73(5-6), 281-289. https://doi.org/10.1159/000132393

Epidermal growth factor receptor-directed therapy in esophageal cancer. / Pande, A. U.; Iyer, R. V.; Rani, A.; Maddipatla, S.; Yang, G. Y.; Nwogu, C. E.; Black, J. D.; Levea, C. M.; Javle, M. M.

In: ONCOLOGY, Vol. 73, No. 5-6, 01.06.2008, p. 281-289.

Research output: Contribution to journalReview article

Pande, AU, Iyer, RV, Rani, A, Maddipatla, S, Yang, GY, Nwogu, CE, Black, JD, Levea, CM & Javle, MM 2008, 'Epidermal growth factor receptor-directed therapy in esophageal cancer', ONCOLOGY, vol. 73, no. 5-6, pp. 281-289. https://doi.org/10.1159/000132393
Pande AU, Iyer RV, Rani A, Maddipatla S, Yang GY, Nwogu CE et al. Epidermal growth factor receptor-directed therapy in esophageal cancer. ONCOLOGY. 2008 Jun 1;73(5-6):281-289. https://doi.org/10.1159/000132393
Pande, A. U. ; Iyer, R. V. ; Rani, A. ; Maddipatla, S. ; Yang, G. Y. ; Nwogu, C. E. ; Black, J. D. ; Levea, C. M. ; Javle, M. M. / Epidermal growth factor receptor-directed therapy in esophageal cancer. In: ONCOLOGY. 2008 ; Vol. 73, No. 5-6. pp. 281-289.
@article{2146c03fd23949b89b1f11e43ae05f70,
title = "Epidermal growth factor receptor-directed therapy in esophageal cancer",
abstract = "Esophageal adenocarcinoma (EAC) is one of the fastest growing malignancies in the US. The long-term survival of patients with this cancer remains poor; only 25{\%} of patients undergoing surgical excision are alive after 5 years. Multimodal programs that incorporate radiotherapy, chemotherapy and surgery for localized tumors may result in a modest survival advantage. However, significant strides in this disease can result from the inclusion of targeted therapies. The epidermal growth factor receptor (EGFR) family represents one such target and is receiving increasing attention due to the advent of specific inhibitors. Studies conducted by us and others have shown that the overexpression of EGFR family signaling intermediates is common in Barrett's esophagus and EAC. In the latter case, EGFR expression may have prognostic significance. EGFR inhibitors, including oral tyrosine kinase inhibitors and monoclonal antibodies, result in a synergistic antitumor effect with chemotherapeutic agents or with radiotherapy. Therefore, several ongoing studies include EGFR-directed therapy either alone or in combination with chemoradiotherapy for this disease. Our study of gefitinib, oxaliplatin and radiotherapy suggested that gefitinib can be safely incorporated into an oxaliplatin-based chemoradiation program for esophageal cancer, although the clinical activity of this combination is modest. Herein, we review the current literature on this subject.",
keywords = "Barrett's esophagus, Epidermal growth factor receptor, Esophageal neoplasms",
author = "Pande, {A. U.} and Iyer, {R. V.} and A. Rani and S. Maddipatla and Yang, {G. Y.} and Nwogu, {C. E.} and Black, {J. D.} and Levea, {C. M.} and Javle, {M. M.}",
year = "2008",
month = "6",
day = "1",
doi = "10.1159/000132393",
language = "English (US)",
volume = "73",
pages = "281--289",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "5-6",

}

TY - JOUR

T1 - Epidermal growth factor receptor-directed therapy in esophageal cancer

AU - Pande, A. U.

AU - Iyer, R. V.

AU - Rani, A.

AU - Maddipatla, S.

AU - Yang, G. Y.

AU - Nwogu, C. E.

AU - Black, J. D.

AU - Levea, C. M.

AU - Javle, M. M.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Esophageal adenocarcinoma (EAC) is one of the fastest growing malignancies in the US. The long-term survival of patients with this cancer remains poor; only 25% of patients undergoing surgical excision are alive after 5 years. Multimodal programs that incorporate radiotherapy, chemotherapy and surgery for localized tumors may result in a modest survival advantage. However, significant strides in this disease can result from the inclusion of targeted therapies. The epidermal growth factor receptor (EGFR) family represents one such target and is receiving increasing attention due to the advent of specific inhibitors. Studies conducted by us and others have shown that the overexpression of EGFR family signaling intermediates is common in Barrett's esophagus and EAC. In the latter case, EGFR expression may have prognostic significance. EGFR inhibitors, including oral tyrosine kinase inhibitors and monoclonal antibodies, result in a synergistic antitumor effect with chemotherapeutic agents or with radiotherapy. Therefore, several ongoing studies include EGFR-directed therapy either alone or in combination with chemoradiotherapy for this disease. Our study of gefitinib, oxaliplatin and radiotherapy suggested that gefitinib can be safely incorporated into an oxaliplatin-based chemoradiation program for esophageal cancer, although the clinical activity of this combination is modest. Herein, we review the current literature on this subject.

AB - Esophageal adenocarcinoma (EAC) is one of the fastest growing malignancies in the US. The long-term survival of patients with this cancer remains poor; only 25% of patients undergoing surgical excision are alive after 5 years. Multimodal programs that incorporate radiotherapy, chemotherapy and surgery for localized tumors may result in a modest survival advantage. However, significant strides in this disease can result from the inclusion of targeted therapies. The epidermal growth factor receptor (EGFR) family represents one such target and is receiving increasing attention due to the advent of specific inhibitors. Studies conducted by us and others have shown that the overexpression of EGFR family signaling intermediates is common in Barrett's esophagus and EAC. In the latter case, EGFR expression may have prognostic significance. EGFR inhibitors, including oral tyrosine kinase inhibitors and monoclonal antibodies, result in a synergistic antitumor effect with chemotherapeutic agents or with radiotherapy. Therefore, several ongoing studies include EGFR-directed therapy either alone or in combination with chemoradiotherapy for this disease. Our study of gefitinib, oxaliplatin and radiotherapy suggested that gefitinib can be safely incorporated into an oxaliplatin-based chemoradiation program for esophageal cancer, although the clinical activity of this combination is modest. Herein, we review the current literature on this subject.

KW - Barrett's esophagus

KW - Epidermal growth factor receptor

KW - Esophageal neoplasms

UR - http://www.scopus.com/inward/record.url?scp=45549103190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45549103190&partnerID=8YFLogxK

U2 - 10.1159/000132393

DO - 10.1159/000132393

M3 - Review article

C2 - 18477853

AN - SCOPUS:45549103190

VL - 73

SP - 281

EP - 289

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 5-6

ER -